AXDX Relative Valuation
AXDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AXDX is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for AXDX's competitors is 2.17, providing a benchmark for relative valuation. Accelerate Diagnostics Inc Corp (AXDX) exhibits a P/S ratio of 0.27, which is -87.37% above the industry average. Given its robust revenue growth of -6.97%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
AAPL
Apple Inc
206.440
USD
-1.12%
AVGO
Broadcom Inc
231.090
USD
+0.20%
XOM
Exxon Mobil Corp
105.025
USD
-1.36%
NVDA
NVIDIA Corp
134.305
USD
-0.93%
TSLA
Tesla Inc
343.730
USD
+0.48%
ORCL
Oracle Corp
160.090
USD
+0.28%
MSFT
Microsoft Corp
457.540
USD
-0.29%
AMZN
Amazon.com Inc
203.910
USD
-1.09%
WMT
Walmart Inc
97.755
USD
-0.37%
META
Meta Platforms Inc
635.850
USD
-0.72%
FAQ
Is Accelerate Diagnostics Inc (AXDX) currently overvalued or undervalued?
Accelerate Diagnostics Inc (AXDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.27 is considered Undervalued compared with the five-year average of 14.13. The fair price of Accelerate Diagnostics Inc (AXDX) is between 0.35 to 0.58 according to relative valuation methord. Compared to the current price of 0.05 USD , Accelerate Diagnostics Inc is Undervalued By 85.67% .
What is Accelerate Diagnostics Inc (AXDX) fair value?
How does AXDX's valuation metrics compare to the industry average?
What is the current P/B ratio for Accelerate Diagnostics Inc (AXDX) as of May 20 2025?
What is the current FCF Yield for Accelerate Diagnostics Inc (AXDX) as of May 20 2025?
What is the current Forward P/E ratio for Accelerate Diagnostics Inc (AXDX) as of May 20 2025?